Prostate
-
Publication Venue For
- Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCH.. 77:1592-1600. 2017
- Association of Obesity-Related Hemodilution of Prostate-Specific Antigen, Dihydrotestosterone, and Testosterone.. 77:466-470. 2017
- Number of Unfavorable Intermediate-Risk Factors Predicts Pathologic Upstaging and Prostate Cancer-Specific Mortality Following Radical Prostatectomy: Results From the SEARCH Database.. 77:154-163. 2017
- Loss of MyD88 leads to more aggressive TRAMP prostate cancer and influences tumor infiltrating lymphocytes. 75:463-473. 2015
- Patient preferences for treatments to delay bone metastases.. 74:1488-1497. 2014
- Enrichment of putative prostate cancer stem cells after androgen deprivation: Upregulation of pluripotency transactivators concurs with resistance to androgen deprivation in LNCaP cell lines. 73:1378-1390. 2013
- Characteristics of baseline PSA and PSA velocity in young men without prostate cancer: Racial differences.. 72:173-180. 2012
- Emerging treatment options for patients with castration-resistant prostate cancer.. 72:338-349. 2012
- PC3 is a cell line characteristic of prostatic small cell carcinoma. 71:1668-1679. 2011
- Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer. 69:787-798. 2009
- Androgen receptor mediates the expression of UDP-glucuronosyltransferase 2 B15 and B17 genes. 68:839-848. 2008
- Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis.. 68:11-19. 2008
- Genome-wide linkage of 77 families from the African American Hereditary Prostate Cancer study (AAHPC).. 67:22-31. 2007
- Immunohistochemical characterization of neuroendocrine cells in prostate cancer. 66:1399-1406. 2006
- Lysophosphatidic acid promotes survival of androgen-insensitive prostate cancer PC3 cells via activation of NF-kappaB.. 61:105-113. 2004
- Selenomethionine does not affect PSA secretion independent of its effect on LNCaP cell growth.. 54:315-321. 2003
- Inhibition of human chorionic gonadotropin beta-subunit modulates the mitogenic effect of c-myc in human prostate cancer cells.. 53:200-210. 2002
- Insulin-like growth factor binding protein-3 induces early apoptosis in malignant prostate cancer cells and inhibits tumor formation in vivo.. 51:141-152. 2002
- Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin.. 48:71-78. 2001
- Reduced expression of hMSH2 and hMLH1 and risk of prostate cancer: a case-control study.. 47:269-275. 2001
- Rational basis for Trk inhibition therapy for prostate cancer.. 45:140-148. 2000
- Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers.. 42:295-303. 2000
- Mutational analysis of the TrkA gene in prostate cancer.. 36:172-180. 1998
- Prostate-specific antigen-detected prostate cancer (stage T1c): an analysis of whole-mount prostatectomy specimens.. 32:59-64. 1997
- Mutations of the p16 gene product are rare in prostate cancer.. 30:188-194. 1997
- 6-Methylene progesterone is cytotoxic to human cancer cell lines independent of its 5-alpha-reductase activity.. 26:28-34. 1995
- A coaxial microwave applicator for transurethral hyperthermia of the prostate.. 22:125-138. 1993
- Infrequent RAS oncogene mutations in human prostate cancer.. 20:327-338. 1992
- Establishment of a longāterm adenocarcinoma of the prostate cell line in the nude mouse. 7:369-376. 1985
- A serologic approach to the definition of human prostatic carcinoma antigens.. 2:369-380. 1981